RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Exact Sciences Stock

Exact Sciences Revenue 2024

Exact Sciences Revenue

2.81 B USD

Ticker

EXAS

ISIN

US30063P1057

WKN

590273

In 2024, Exact Sciences's sales reached 2.81 B USD, a 12.41% difference from the 2.5 B USD sales recorded in the previous year.

The Exact Sciences Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e4.8538,03
2028e4.4241,75
2027e4.0545,60
2026e3.4952,87
2025e3.1458,83
2024e2.8165,68
20232.573,83
20222.0872,44
20211.7774,04
20201.4976,24
20190.8875,27
20180.4574,32
20170.2770,56
20160.154,53
20150.0437,82
20140-138,89
20130100,00
20120100,00
2011097,62
20100.01100,00
2009097,92
2008-0100,00
2007094,44
2006081,25
2005086,05
2004089,80

Exact Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Exact Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Exact Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Exact Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Exact Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Exact Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Exact Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Exact Sciences’s growth potential.

Exact Sciences Revenue, EBIT and net profit per share

DateExact Sciences RevenueExact Sciences EBITExact Sciences Net Income
2029e4.85 B undefined0 undefined715.48 M undefined
2028e4.42 B undefined544.65 M undefined416.26 M undefined
2027e4.05 B undefined278.3 M undefined242.91 M undefined
2026e3.49 B undefined175 M undefined70.19 M undefined
2025e3.14 B undefined-18.15 M undefined-64.02 M undefined
2024e2.81 B undefined-192.52 M undefined-210.83 M undefined
20232.5 B undefined-214.39 M undefined-204.15 M undefined
20222.08 B undefined-577.5 M undefined-623.5 M undefined
20211.77 B undefined-750.2 M undefined-595.6 M undefined
20201.49 B undefined-145.4 M undefined-823.6 M undefined
2019876.3 M undefined-233.8 M undefined-213.1 M undefined
2018454.5 M undefined-159.5 M undefined-175.1 M undefined
2017266 M undefined-118.3 M undefined-114.4 M undefined
201699.4 M undefined-169 M undefined-167.2 M undefined
201539.4 M undefined-159.1 M undefined-157.8 M undefined
20141.8 M undefined-100.5 M undefined-100 M undefined
20134.1 M undefined-46.8 M undefined-46.5 M undefined
20124.1 M undefined-52.6 M undefined-52.4 M undefined
20114.2 M undefined-28.8 M undefined-28.7 M undefined
20105.3 M undefined-11.8 M undefined-11.6 M undefined
20094.8 M undefined-9.2 M undefined-9.1 M undefined
2008-900,000 undefined-9.4 M undefined-9.7 M undefined
20071.8 M undefined-11.6 M undefined-12 M undefined
20064.8 M undefined-13.5 M undefined-12.9 M undefined
20054.3 M undefined-15 M undefined-14.5 M undefined
20044.9 M undefined-19.2 M undefined-18.5 M undefined

Exact Sciences stock margins

The Exact Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Exact Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Exact Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Exact Sciences's sales revenue. A higher gross margin percentage indicates that the Exact Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Exact Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Exact Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Exact Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Exact Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Exact Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Exact Sciences Margin History

Exact Sciences Gross marginExact Sciences Profit marginExact Sciences EBIT marginExact Sciences Profit margin
2029e73.83 %0 %14.74 %
2028e73.83 %12.32 %9.42 %
2027e73.83 %6.88 %6 %
2026e73.83 %5.01 %2.01 %
2025e73.83 %-0.58 %-2.04 %
2024e73.83 %-6.85 %-7.5 %
202373.83 %-8.58 %-8.17 %
202272.44 %-27.71 %-29.91 %
202174.04 %-42.45 %-33.7 %
202076.24 %-9.75 %-55.22 %
201975.27 %-26.68 %-24.32 %
201874.32 %-35.09 %-38.53 %
201770.56 %-44.47 %-43.01 %
201654.53 %-170.02 %-168.21 %
201537.82 %-403.81 %-400.51 %
2014-138.89 %-5,583.33 %-5,555.56 %
2013100 %-1,141.46 %-1,134.15 %
2012100 %-1,282.93 %-1,278.05 %
201197.62 %-685.71 %-683.33 %
2010100 %-222.64 %-218.87 %
200997.92 %-191.67 %-189.58 %
2008100 %1,044.44 %1,077.78 %
200794.44 %-644.44 %-666.67 %
200681.25 %-281.25 %-268.75 %
200586.05 %-348.84 %-337.21 %
200489.8 %-391.84 %-377.55 %

Exact Sciences Aktienanalyse

What does Exact Sciences do?

Exact Sciences Corp is a US-based company specializing in the development, manufacturing, and marketing of diagnostics. It was founded in 1995 by Kevin T. Conroy and is headquartered in Madison, Wisconsin. The company's main focus is on cancer diagnostics. It has developed an innovative test called the Cologuard test, which is a simple, non-invasive method for detecting colorectal cancer. The test can provide accurate results by analyzing a stool sample from the patient. The Cologuard test is FDA approved and recommended by physicians in the US. Exact Sciences has also developed an extensive portfolio of liquid biopsy tests, which can help detect cancer in its early stages by identifying changes in the patient's blood. The company aims to expand its position in the market for non-invasive cancer diagnostics. Originally founded as an oncology diagnostics company specializing in the development of tests for early tumor detection, Exact Sciences expanded its focus to colorectal cancer diagnostics in 2009 after acquiring the rights to a patented biomarker. The company has experienced rapid growth in recent years and has become a leader in the field of non-invasive cancer diagnostics. It has made several acquisitions, including the acquisition of Genomic Health, a provider of cancer diagnostics and molecular tests. Exact Sciences is divided into two business segments: 1. Diagnostics Exact Sciences develops and distributes diagnostics for the detection of various forms of cancer. The company has a range of products on the market, including: - Cologuard: A test for detecting colorectal cancer - Oncotype DX: A test for detecting various types of breast cancer - Oncotype MAP: A test for detecting colorectal and gastric cancer - Oncotype IQ: A platform for detecting various types of cancer 2. Research and Development Exact Sciences also conducts research and development in the field of cancer diagnostics. The company is working on developing tests for detecting many types of cancer in their early stages. It has also formed partnerships with other companies and organizations to support its research in this field. In conclusion, Exact Sciences Corp is an innovative company specializing in the development of diagnostics for the detection of various types of cancer. The company has achieved a strong market position in non-invasive cancer diagnostics and aims to further expand its product range. With the Cologuard test and its other diagnostics, the company has saved many lives and will continue to contribute to the early detection and treatment of cancer in the future. Exact Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Exact Sciences's Sales Figures

The sales figures of Exact Sciences originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Exact Sciences’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Exact Sciences's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Exact Sciences’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Exact Sciences stock

How much revenue did Exact Sciences generate this year?

Exact Sciences has achieved a revenue of 2.81 B USD this year.

How much was the turnover of the company Exact Sciences compared to the previous year?

The revenue of Exact Sciences has increased by 12.41% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Exact Sciences?

The revenue of Exact Sciences is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Exact Sciences measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Exact Sciences so important for investors?

The revenue of Exact Sciences is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Exact Sciences pay?

Over the past 12 months, Exact Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exact Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Exact Sciences?

The current dividend yield of Exact Sciences is .

When does Exact Sciences pay dividends?

Exact Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Exact Sciences?

Exact Sciences paid dividends every year for the past 0 years.

What is the dividend of Exact Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Exact Sciences located?

Exact Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Exact Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Exact Sciences from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Exact Sciences pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Exact Sciences in the year 2023?

In the year 2023, Exact Sciences distributed 0 USD as dividends.

In which currency does Exact Sciences pay out the dividend?

The dividends of Exact Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Exact Sciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Exact Sciences

Our stock analysis for Exact Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exact Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.